Literature DB >> 31218417

[Psoriasis therapy in pregnancy : Consultation of pregnant patients].

B Stephan1, M A Radtke2, M Augustin2.   

Abstract

Systemic therapy of pregnant patients with psoriasis requires special attention and has to be adapted to disease activity throughout the pregnancy. With the approval of the first tumor necrosis factor alpha inhibitors for the treatment of these patients, a new range of options has to be discussed with the women. If the inflammatory presentation of the psoriasis demands systemic therapy, the decision for treatment should be made as early as possible, preferably before the onset of pregnancy.

Entities:  

Keywords:  Active inflammation; Biological products; Desire to have children; Immunomodulatory therapy; TNF-alpha inhibitors

Mesh:

Substances:

Year:  2019        PMID: 31218417     DOI: 10.1007/s00105-019-4444-2

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  12 in total

1.  Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding.

Authors:  Birgitte G Berthelsen; Hans Fjeldsøe-Nielsen; Christoffer T Nielsen; Ellinor Hellmuth
Journal:  Rheumatology (Oxford)       Date:  2010-06-26       Impact factor: 7.580

2.  Psoriasis and pregnancy outcomes: a nationwide population-based study.

Authors:  Ya-Wen Yang; Chin-Shyan Chen; Yi-Hua Chen; Herng-Ching Lin
Journal:  J Am Acad Dermatol       Date:  2011-01       Impact factor: 11.527

3.  Evolution of maternofetal transport of immunoglobulins during human pregnancy.

Authors:  A Malek; R Sager; P Kuhn; K H Nicolaides; H Schneider
Journal:  Am J Reprod Immunol       Date:  1996-11       Impact factor: 3.886

4.  Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Authors:  Robert E Kalb; David F Fiorentino; Mark G Lebwohl; John Toole; Yves Poulin; Arnon D Cohen; Kavitha Goyal; Steven Fakharzadeh; Stephen Calabro; Marc Chevrier; Wayne Langholff; Yin You; Craig L Leonardi
Journal:  JAMA Dermatol       Date:  2015-09       Impact factor: 10.282

Review 5.  The use of biologics in pregnant patients with rheumatic disease.

Authors:  Monika Østensen
Journal:  Expert Rev Clin Pharmacol       Date:  2017-03-22       Impact factor: 5.045

6.  Pregnancy outcomes in women with moderate-to-severe psoriasis.

Authors:  E Cohen-Barak; Z Nachum; D Rozenman; M Ziv
Journal:  J Eur Acad Dermatol Venereol       Date:  2010-11-25       Impact factor: 6.166

7.  Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.

Authors:  Uma Mahadevan; Douglas C Wolf; Marla Dubinsky; Antoine Cortot; Scott D Lee; Corey A Siegel; Thomas Ullman; Sarah Glover; John F Valentine; David T Rubin; Jocelyn Miller; Maria T Abreu
Journal:  Clin Gastroenterol Hepatol       Date:  2012-11-28       Impact factor: 11.382

8.  Pregnancy outcome in women with psoriasis.

Authors:  Gila Ben-David; Eyal Sheiner; Mordechai Hallak; Amalia Levy
Journal:  J Reprod Med       Date:  2008-03       Impact factor: 0.142

9.  The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.

Authors:  Carina Götestam Skorpen; Maria Hoeltzenbein; Angela Tincani; Rebecca Fischer-Betz; Elisabeth Elefant; Christina Chambers; Josè da Silva; Catherine Nelson-Piercy; Irene Cetin; Nathalie Costedoat-Chalumeau; Radboud Dolhain; Frauke Förger; Munther Khamashta; Guillermo Ruiz-Irastorza; Angela Zink; Jiri Vencovsky; Maurizio Cutolo; Nele Caeyers; Claudia Zumbühl; Monika Østensen
Journal:  Ann Rheum Dis       Date:  2016-02-17       Impact factor: 19.103

10.  Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study.

Authors:  Xavier Mariette; Frauke Förger; Bincy Abraham; Ann D Flynn; Anna Moltó; René-Marc Flipo; Astrid van Tubergen; Laura Shaughnessy; Jeff Simpson; Marie Teil; Eric Helmer; Maggie Wang; Eliza F Chakravarty
Journal:  Ann Rheum Dis       Date:  2017-10-13       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.